Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra(TM) in Age-Related Knee Osteoarthritis

Stock Information for Enlivex Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enlivex Ltd.

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra(TM) in Patients with Osteoarthritis
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.